Reimagine Care expanded its AI-enabled virtual oncology care program with Moffitt Cancer Center, building on early outcomes during an initial implementation phase related to patient engagement, symptom management, and acute care utilization. The model extends cancer care beyond scheduled visits through continuous support powered by Reimagine Care’s AI-powered assistant, Remi, and a dedicated oncology virtual care team. Press release. 

Verana Health announced its continued investment in women's cancers with the rapid expansion of its ovarian cancer database. The database includes a variable-rich array of curated RWD from both academic and community cancer centers throughout the U.S., offering researchers comprehensive longitudinal insights into disease detection, treatment, and patient outcomes. The ovarian cancer dataset delivers high completeness across critical clinical variables that drive research and treatment decision-making, including molecular testing, treatment sequencing, disease state, and outcomes. Press release. 

QuartzBio announced a strategic growth investment and controlling interest from Eir Partners. The investment enables QuartzBio to accelerate enhancements across its platform and operating model, including: expanded portfolio‑scale interoperability across CROs, labs, and clinical systems; deeper AI‑driven automation for workflow management, risk detection, and data completeness; enhanced analytics and benchmarking for multi-trial decision‑making; increased enterprise scalability, security, and global compliance; and expanded customer support and implementation capacity to match growing adoption. Press release. 

uMotif launched its new Scientific Consulting Services. uMotif's Scientific Consulting Services includes scientific oversight and input across all vital design areas:   clinical outcome assessments, DHTs, study design and methodology, and navigating regulatory best practices, as well as COA licensing management. The new offer also includes COA licensing management and translation services. Press release. 

Flatiron Health launched Flatiron Telescope, a next-generation AI-powered platform designed to help life sciences teams and researchers find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand. Built on Flatiron’s industry-leading real-world data and powered by its multi-agent adaptive analytics engine, Flatiron Telescope enables teams across clinical development, RWE, and commercial functions to move from hypothesis to insight in minutes instead of months. Press release. 

b.well Connected Health and myTomorrows announced a partnership to fundamentally improve how patients are connected to clinical trials. The partnership combines b.well's FHIR-based platform, which connects health data from nearly 2.4 million providers, more than 330 health plans, multiple state HIEs, laboratories, pharmacies, and over 350 wearables, health sensors and biomarkers, into complete, verified health data, with myTomorrows' proven AI-powered clinical trial pre-screening and matching technology. Together, the companies will enable pharmaceutical sponsors and trial sites to compliantly identify, screen, and ultimately enroll eligible patients faster while dramatically reducing the burden placed on individuals already navigating some of the most challenging moments of their lives. Press release. 

Veeva Systems announced Veeva Falcon, an agentic platform and standard agents for life sciences’ major drug development processes. Falcon works with Veeva Development Cloud applications in clinical, regulatory, and safety to reduce cost, increase speed, and maintain compliance for biopharmas of all sizes. The initial focus areas are trial master file document intake and quality control, health authority correspondence in regulatory, and safety case triage and intake. Press release. 

Cellular Origins agreed to collaborate with Immatics in utilizing Cellular Origins’ automated mobile robotic platform, Constellation, within certain parts of the company’s manufacturing processes. The collaboration will explore how automation technologies can further contribute to more efficient and scalable manufacturing processes for next-generation cell therapies. Press release. 

RTI International announced a partnership and strategic equity investment in Navidence. As part of the investment, RTI will engage with Navidence through a planned strategic collaboration focused on product evolution and commercialization. The collaboration will combine RTI's scientific leadership and real-world research expertise with Navidence's data science and medical informatics capabilities to help standardize disease definitions across the industry, strengthen research insights across programs and support more effective therapeutic interventions for patients. Press release.